Michael A Gibson, M.D.
Investigator
Dr. Michael A. Gibson is an Advanced Heart Failure and Transplant Cardiologist with extensive expertise in the management of complex cardiovascular disease. He serves as an Associate Professor at the University of California, Davis, where he provides advanced clinical care while contributing to medical education and multidisciplinary research. Dr. Gibson completed his medical degree at the Albert Einstein College of Medicine, followed by residency and fellowships in Cardiology and Advanced Heart Failure at the University of California, San Diego. His clinical and research interests span cardiogenic shock, mechanical circulatory support, heart transplantation, and innovative heart failure therapies. He has served as a principal and co-investigator on multiple national and international heart failure trials and is an active lecturer for academic institutions and professional societies. A Fellow of the American College of Cardiology, Dr. Gibson is recognized for his commitment to advancing heart failure care through research, education, and compassionate patient management.
Clinical trials
- Clinical trial
Heart Failure - TEAM-HF
Trial to Evaluate Safety and Effectiveness of Mechanical Circulatory Support in Patients with Advancing Heart Failure
Status: Open to Enrollment
- Clinical trial
Heart Failure COMET-HF
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF)
Status: Open to Enrollment
- Clinical trial
Heart Failure CONFIRMATION-HF
Combined Efficacy and Safety of an Early, Intensive, Management Strategy with Finerenone and SGLT2 Inhibitor in Patients Hospitalized with Heart Failure (CONFIRMATION-HF)
Status: Open to Enrollment
- Clinical trial
Heart Failure FINALITY-HF
A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
Status: Open to Enrollment
- Clinical trial
Heart Failure REDEFINE-HF
Randomized Trial to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Heart Failure Patients With Left Ventricular Ejection Fraction Greater Than or Equal to 40% Hospitalized Due to an Episode of Acute Decompensated Heart Failure (REDEFINE-HF)
Status: Open to Enrollment